Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest Expenses (2016 - 2026)

Ironwood Pharmaceuticals' Interest Expenses history spans 16 years, with the latest figure at $7.9 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 11.53% to $7.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.7 million, a 0.87% decrease, with the full-year FY2025 number at $32.7 million, down 0.87% from a year prior.
  • Interest Expenses hit $7.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $8.4 million in the prior quarter.
  • Over the last five years, Interest Expenses for IRWD hit a ceiling of $9.8 million in Q3 2023 and a floor of $1.5 million in Q3 2022.
  • Historically, Interest Expenses has averaged $6.3 million across 5 years, with a median of $7.8 million in 2021.
  • Biggest five-year swings in Interest Expenses: plummeted 80.81% in 2022 and later soared 545.6% in 2023.
  • Tracing IRWD's Interest Expenses over 5 years: stood at $8.0 million in 2021, then plummeted by 80.81% to $1.5 million in 2022, then skyrocketed by 451.97% to $8.4 million in 2023, then increased by 5.83% to $8.9 million in 2024, then dropped by 11.53% to $7.9 million in 2025.
  • Business Quant data shows Interest Expenses for IRWD at $7.9 million in Q4 2025, $8.4 million in Q3 2025, and $8.4 million in Q2 2025.